New ruthenium-based drugs show promise for killing cancer cells

June 11, 2012

A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug.

Cisplatin is a common platinum-based cancer drug. But while cisplatin kills , it also attacks healthy cells, causing debilitating side effects. Ruthenium is a rare transition metal also belonging to the platinum group of the periodic table, and the UK researchers developed two new ruthenium complexes designed to kill cancer cells while preserving healthy cells.

These complexes are inert in the dark, but when activated with light, they become up to 200 times as toxic, and up to three times as potent as cisplatin against tumor cells.

Published in the , the study examined the effects of these new complexes on lung cancer and . Edith Glazer, UK assistant professor of chemistry and principal investigator for the study, hopes to move these compounds forward in more biological testing soon.

"Coordination chemistry has proven to be an elegant method to rapidly synthesize a family of molecules," Glazer said. "We anticipate that this will prove advantageous in allowing us to make chemical modifications to optimize properties as needed as we move forward into animal studies."

Explore further: A silver bullet to beat cancer?

Related Stories

A silver bullet to beat cancer?

February 2, 2012
The internet is awash with stories of how silver can be used to treat cancer. Now, lab tests have shown that it is as effective as the leading chemotherapy drug - and may have fewer side-effects.

Recommended for you

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.